David J. Wambeke net worth and biography

David Wambeke Biography and Net Worth

Chief Business Officer of NeuroOne Medical Technologies

Mr. Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company’s lead biologic into preeclampsia, a hypertensive disorder of pregnancy. He established and oversaw a first-in-pregnancy Phase 2 clinical trial that delivered positive results and contributed to substantial shareholder value creation. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army and during a deployment in Baghdad, Iraq, Mr. Wambeke was wounded in combat and awarded the Purple Heart. Mr. Wambeke received a B.S. from the University of Minnesota.

What is David J. Wambeke's net worth?: The estimated net worth of David J. Wambeke is at least $226.00 thousand as of August 27th, 2026. Mr. Wambeke owns 199,999 shares of NeuroOne Medical Technologies stock worth more than $225,999 as of October 7th. This net worth approximation does not reflect any other assets that Mr. Wambeke may own. Learn More about David J. Wambeke's net worth.
How do I contact David J. Wambeke?: The corporate mailing address for Mr. Wambeke and other NeuroOne Medical Technologies executives is 7599 Anagram DR, Eden Prairie, MN, 55344. NeuroOne Medical Technologies can also be reached via phone at (952) 426-1383 and via email at [email protected]. Learn More on David J. Wambeke's contact information.
Has David J. Wambeke been buying or selling shares of NeuroOne Medical Technologies?: David J. Wambeke has not been actively trading shares of NeuroOne Medical Technologies during the past quarter. Most recently, on Thursday, August 27th, David J. Wambeke bought 33,333 shares of NeuroOne Medical Technologies stock. The stock was acquired at an average cost of $2.01 per share, with a total value of $66,999.33. Following the completion of the transaction, the insider now directly owns 199,999 shares of the company's stock, valued at $401,997.99. Learn More on David J. Wambeke's trading history.
Who are NeuroOne Medical Technologies' active insiders?: NeuroOne Medical Technologies' insider roster includes Mark Christianson (Director), David Rosa (CEO), and David Wambeke (Chief Business Officer). Learn More on NeuroOne Medical Technologies' active insiders.
Are insiders buying or selling shares of NeuroOne Medical Technologies?: During the last year, NeuroOne Medical Technologies insiders bought shares 2 times. They purchased a total of 199,999 shares worth more than $736,996.65. During the last year, insiders at the sold shares 5 times. They sold a total of 12,438 shares worth more than $43,502.40. The most recent insider tranaction occured on August, 27th when insider David J. Wambeke bought 33,333 shares worth more than $66,999.33. Insiders at NeuroOne Medical Technologies own 11.8% of the company. Learn More about insider trades at NeuroOne Medical Technologies.
Information on this page was last updated on 8/27/2026.

David J. Wambeke Insider Trading History at NeuroOne Medical Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2026	Buy	33,333	$2.01	$66,999.33	199,999
3/1/2026	Buy	166,666	$4.02	$669,997.32	166,666

David J. Wambeke Buying and Selling Activity at NeuroOne Medical Technologies

NeuroOne Medical Technologies Company Overview

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

Today's Range

Now: $1.13

$1.10

$1.16

50 Day Range

MA: $1.60

$0.99

$2.18

2 Week Range

Now: $1.13

$0.96

$6.72

Volume

24,476 shs

Average Volume

138,266 shs

Market Capitalization

$10.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77